Empagliflozin for High Blood Pressure

(NEURO-EMPA Trial)

KB
NC
Overseen ByNicholas Carlini, PHD
Age: 18+
Sex: Any
Trial Phase: Phase 4
Sponsor: Kanokwan Bunsawat
Prior Safety DataThis treatment has passed at least one previous human trial

What You Need to Know Before You Apply

What is the purpose of this trial?

The goal of this clinical trial is to examine whether empagliflozin, a sodium-glucose co-transporter 2 (SGLT2) inhibitor, improves vascular and autonomic function in adults with prehypertension. The main questions this clinical trial aims to answer are:

1. Does empagliflozin improve endothelial function?

2. Does empagliflozin improve sympathetic nervous system function?

This clinical trial employs a double-blind, placebo-controlled crossover study lasting up to 6 weeks for participants with prehypertension and up to 2 weeks for normotensive participants. Participants with prehypertension will take empagliflozin or placebo for 2 weeks, separated by a 2-week washout. Normotensive participants will complete baseline, pre-treatment visits only and will serve as a control group.

Who Is on the Research Team?

KB

Kanokwan Bunsawat, PHD

Principal Investigator

University of Iowa

Are You a Good Fit for This Trial?

This trial is for adults with prehypertension (slightly high blood pressure) or normal blood pressure. Participants should not have other major health issues that could interfere with the study.

Inclusion Criteria

Body mass index 18-35 kg/m2
Able to give informed consent
Normotensive (control group) with Systolic <120 mmHg and Diastolic <80 mmHg
See 2 more

Exclusion Criteria

Psychiatric or psychological disorders
I am receiving hormone-based therapy.
BMI >35 kg/m2
See 21 more

What Are the Treatments Tested in This Trial?

Interventions

  • Empagliflozin

Trial Overview

The study tests whether empagliflozin, a diabetes medication, can improve blood vessel and nervous system function compared to a placebo. It uses a double-blind crossover design where participants receive both treatments at different times.

How Is the Trial Designed?

2

Treatment groups

Experimental Treatment

Placebo Group

Group I: EmpagliflozinExperimental Treatment2 Interventions
Group II: PlaceboPlacebo Group2 Interventions

Find a Clinic Near You

Who Is Running the Clinical Trial?

Kanokwan Bunsawat

Lead Sponsor